$Sarepta Therapeutics (SRPT.US)$ found em

Hey, mooers!
The Global Paper Trading Challenge has been underway for a week now, and we're thrilled to have over 75,000 participants from around the globe!
In the U.S. region, more than 85 participants have achieved weekly virtual gains exceeding 10%. The most popular stock traded in our Challenge last week? $Bright Minds Biosciences (DRUG.US)$, a pharmaceutical company that just received FDA approval for its new drug. This week, $GRI Bio (GRI.US)$ is curren...

$iShares MSCI Intl Momentum Factor ETF (IMTM.US)$ not bad

$PowerShares Exchange-Traded Fund Trust II (IDMO.US)$ good rating, I might

$Takeda Pharmaceutical (TAK.US)$ Takeda Says Primary And Key Secondary Endpoints Were Met In Narcolepsy Type 1 Phase 2b Trial;
The NT1 trial TAK-861-2001 evaluating TAK-861 in 112 patients demonstrated statistically significant and clinically meaningful improvement in objective and subjective measures of wakefulness compared to placebo at week 8 including on the primary endpoint Maintenance of Wakefulness Test (MWT) (p < 0.001).
Plans To Initiate Global Phase 3 Trials Of TAK-861 In Narcolep...